Article Details

Immix Biopharma Surpasses 50% Enrollment Milestone in NEXICART-2 Clinical Trial for AL ...

Retrieved on: 2025-09-18 20:00:12

Tags for this article:

Click the tags to see associated articles and topics

Immix Biopharma Surpasses 50% Enrollment Milestone in NEXICART-2 Clinical Trial for AL .... View article details on hiswai:

Excerpt

Immix Biopharma surpassed 50% enrollment in NEXICART-2 trial for CAR-T therapy targeting relapsed/re.

Article found on: www.quiverquant.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo